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Abstract 
Multiple sclerosis (MS) is a neurodegenerative disease with severe effects on motor and 
cognitive function. Despite the evolution of knowledge in recent decades, the causes and the 
exact mechanisms that originate the disease are still unknown. Recent studies demonstrated 
that S100B protein expression is increased in MS patients and that its high levels are correlated 
with glial reactivity, contributing to the characteristic excessive inflammatory response of this 
disease. We also showed that S100B blockade does not prevent demyelination-associated 
activation of microglia, but it decreases the expression of pro-inflammatory markers. 
Interestingly, microscopic imaging suggested that upon S100B neutralization microglia moved 
to myelin surroundings, where they can play an important role on the clearance of myelin debris 
and remyelination. Thus, we decided to explore whether S100B blockade might modulate the 
reactivity of microglia in an ex vivo demyelinating model. 
Therefore, we first evaluated whether S100B might affect demyelination. Our results 
corroborate a decreased expression of myelin-related protein upon demyelination, which is 
prevented after S100B neutralization. We also quantified the different populations of reactive 
microglia showing that there is an augment of M1 pro-inflammatory reactive microglial cells in 
consequence of demyelination, which is reduced with S100B blockade. Indeed, while upon 
demyelination, we verified an increase of gene expression of pro-inflammatory mediators, 
S100B antibody neutralization partially prevented this effect. In turn, we also observed an 
increase of anti-inflammatory markers usually associated to microglia M2 phenotype, but this 
time S100B blockade maintained their elevated gene expression. In addition, we verified that 
S100B neutralization although not increasing the average number of particles phagocytosed by 
each microglia upon demyelination, it increased the number of microglia with a phagocytic 
ability. Moreover, also the expression of a neuron-derived microglia calming factor, fractalkine, 
was enhanced by S100B neutralization suggesting the shift microglia to a damage repair 
phenotype. 
Overall, these results suggest that by neutralizing S100B during a demyelinating event 
we may prevent the loss of myelin as well as the exacerbation of the inflammatory response, 
indicating that S100B may be a potential therapeutic target to reduce damage in demyelinating 
disorders associated with microglial reactivity, such as MS. 
 
Keywords: Multiple Sclerosis; Microglia; S100B; Demyelination  
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Resumo 
A Esclerose Múltipla (EM) é uma doença neurodegenerativa com efeitos graves a nível 
motor e cognitivo. Apesar da evolução do conhecimento nas últimas décadas, as causas e os 
mecanismos que desencadeiam a doença são ainda desconhecidos. Estudos recentes 
demonstraram que a expressão da proteína S100B está aumentada em doentes com EM e que 
estes níveis elevados estão correlacionados com a reatividade glial, contribuindo para uma 
resposta inflamatória excessiva, característica desta doença. Verificámos igualmente que o 
bloqueio de S100B não previne a ativação da microglia aquando de uma situação de 
desmielinização, mas diminui a expressão de marcadores pro-inflamatórios. Curiosamente, 
imagens de microscopia sugerem que após a neutralização de S100B a microglia movimenta-se 
para a zona da mielina, onde pode desempenhar um papel importante na remoção dos detritos 
de mielina e na remielinização. Assim, decidimos avaliar se o bloqueio de S100B pode modular 
a reatividade da microglia num modelo ex vivo de desmielinização.  
Assim, primeiro avaliámos se a proteína S100B pode afetar a desmielinização. Os nossos 
resultados revelam uma diminuição da expressão génica de uma proteína associada à mielina 
após desmielinização, a qual é prevenida após a neutralização de S100B. Quantificámos ainda 
as diferentes populações de microglia reativa, mostrando que há um aumento das células 
microgliais com um fenótipo M1 pró-inflamatório em consequência da desmielinização, a qual 
é reduzida com o bloqueio de S100B. De facto, a desmielinização leva a um aumento da 
expressão génica de mediadores pró-inflamatórios, enquanto a neutralização de S100B previne 
parcialmente este efeito. Por seu lado, observámos igualmente um aumento dos marcadores 
anti-inflamatórios associados a um fenótipo microglial M2, mas o bloqueio de S100B manteve a 
sua elevada expressão génica. Verificámos ainda que a neutralização de S100B apesar de não 
aumentar o número médio de partículas fagocitadas por cada microglia após desmielinização, 
elevou o número de células microgliais com capacidade fagocítica. Curiosamente, observámos 
igualmente que a expressão de um fator derivado dos neurónios que acalma a reatividade 
microglial, a fractalkina, estava aumentada após neutralização de S100B, sugerindo que a 
microglia possa ter adquirido um fenótipo mais adequado para a reparação do dano. 
De uma maneira geral, estes resultados sugerem que ao neutralizar o S100B podemos 
prevenir a desmielinização bem como uma resposta inflamatória exacerbada, indicando que a 
S100B pode ser um potencial alvo terapêutico para reduzir o dano em doenças desmielinizantes 
associadas à reatividade microglial, tais como a EM. 
 
Palavras-chave: Esclerose Múltipla; Microglia; S100B; Desmielinização  
  
Modulation of microglia reactivity by S100B in Multiple Sclerosis 
xi 
 
Abbreviations 
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I. Introduction 
1. Multiple Sclerosis 
Multiple sclerosis (MS) is a chronic inflammatory and neurodegenerative disorder of the 
Central Nervous System (CNS) which leads to the development of focal demyelinated plaques in 
the white matter (Lassmann, 2011). Furthermore, this disease is characterized by reactivation 
of antigen-presenting cells, microglial activation, production of cytotoxic mediators and 
recruitment of systemic immunocompetent cells that leads to a generalized neural tissue 
damage (Gonsette, 2008). 
Generally, MS starts in young adulthood with neuroinflammation, characterized by the 
CNS infiltration of immune cells across the Blood-Brain-Barrier (BBB), resulting in focal 
demyelinated plaques formation and axonal damage (Compston and Coles, 2008; Lassmann, 
2011; Stadelmann et al., 2011). Depending on plaque location, the symptomatology may be very 
different (Friese et al., 2014; Lassmann et al., 2012). The immune cell invasion may lead to a 
permanent activation of macrophages and microglia in parenchyma that result in demyelination 
and neurodegeneration (Compston and Coles, 2008; Napoli and Neumann, 2010). Therefore, 
the neurodegeneration which starts with acute lymphocytic inflammation may progress towards 
chronic inflammation (Ciccarelli et al., 2014). 
Demyelination is the total or partial loss of the myelin sheath around axons, thus 
compromising the efficient conduction of action potentials (Love, 2006). This loss may be a 
consequence of several factors, including inflammatory processes or viral infections that 
damage myelin sheaths, which are constituted by two main proteins, proteolipid protein (PLP) 
and myelin basic protein (MBP); or the cells that synthetize them, oligodendrocytes in the CNS 
and Schwann Cells in the Peripheral Nervous System (PNS) (Lassmann, 2011; Love, 2006). Axonal 
myelination is a crucial factor for correct signal transmission and any damage in myelin sheaths 
may have serious consequences at cognitive and motor levels (Berger and Reindl, 2007; 
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Lassmann, 2011). Thus, in order to delay disease progression it is important to reduce this 
demyelination, which is a hallmark of MS, or to promote the remyelination process. 
 
1.1. Clinical course of Multiple Sclerosis 
In MS patients usually experience a first neurologic event that is sustained for at least 
24 hours. As showed in Figure I. 1, there are 4 types of MS named in accordance with the clinical 
course of the disease over time: Relapsing-Remitting Multiple Sclerosis (RRMS); Primary-
Progressive Multiple Sclerosis (PPMS); Secondary-Progressive Multiple Sclerosis (SPMS) and 
Progressive-Relapsing Multiple Sclerosis (PRMS).  
The RRMS is the most common form of MS. Initially, about 85% of patients are 
diagnosed with RRMS. This form of MS is characterized by active lesions and temporary relapses 
that can be partially or completely reversible. The majority of this patients with RRMS progress 
to a secondary progressive phase (Lindberg and Kappos, 2006), being designated as SPMS, a 
phase characterized by irreversible deficits and neurodegeneration which are steadily 
increasing, with or without the occurrence of relapses and remissions (Lindberg and Kappos, 
2006). 
 
 
Figure I. 1. Schematic representation of the evolution of disability over time in different types of MS 
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A small percentage of MS patients (~10%) have PPMS that is characterized by a slow and 
continuous progression without relapses (Lindberg and Kappos, 2006). The least common form 
(~5%) is PRMS that is characterized by a steady worsening of neurologic function, with 
occasional relapses but no complete remissions, with or without recovery. Once PRMS is 
progressive from onset, it may be diagnosed as PPMS and subsequently changed to PRMS, when 
a relapse occurs (Lassmann et al., 2012; Milo and Miller, 2014). 
In the course of MS it is possible to distinguish different types of focal plaques of 
demyelination: active, chronic active lesions slowly expanding, inactive lesions and remyelinated 
shadow plaques. The classic active plaques are characterized by high inflammation with 
perivascular infiltrates of lymphocytes and macrophages, a complex architecture being 
commonly detected during the acute or relapsing–remitting stages. The chronic active lesions 
are considered to comprise approximately 50% of the lesions in progressive stage of disease. 
The center of this type of lesion usually does not have myelin nor presents remyelination signals, 
but shows axonal loss. Furthermore, lesions are surrounded by an area of microglial activation 
and initial tissue injury. The inactive lesions are the most frequent type in all stages of the disease 
and present signals of an inefficient remyelination, lack of myelin and axonal loss. In addition, 
the lymphocytic infiltrates and microglial activation are reduced. Finally, the shadow plaques 
result from remyelination and normally present low axonal injury and thinly remyelinated axons. 
This remyelination occurs during the acute inflammation, following myelin debris removal by 
phagocytosis, but it may also be detected in the progressive phase (Lassmann, 2010; Lassmann 
et al., 2012; Love, 2006). 
Once the disease has an early and strong inflammatory component, treatments 
targeting the inflammatory insult have been shown to be effective mostly in the relapsing stage. 
However, in the progressive phase of disease, the anti-inflammatory or immunomodulatory 
treatments used so far showed no clinical relevance (Lassmann, 2011). Thus, a key step for the 
treatment of progressive MS is the development of new therapies for inflammatory and 
neurodegenerative components of the disease. 
 
1.2. The etiology of MS 
The etiology of MS is not fully understood yet, but in the majority of patients, the disease 
progression is characterized by acute relapses (RRMS) leading to a progressive and irreversible 
accumulation of neurological deficits (SPMS). Relapses are the manifestations of inflammatory 
demyelinating lesions in the CNS (Charil and Filippi, 2007; Compston and Coles, 2008; Love, 
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2006). In a primordial phase, the inflammation is a transitory feature and is followed by 
remyelination that contributes to total or partial clinical remission of the symptomatology. 
However, this remyelination may not be complete and, over time, repeated acute insults and 
the failure of reparative system may lead to extensive microglial activation associated with 
irreversible axonal and neuronal loss resulting into neurodegeneration (Charil and Filippi, 2007). 
For many years, the focus of MS research had been on inflammatory white matter 
pathology, once the disease was initially considered to be an immune-mediated demyelinating 
disorder. However, there are results that show axonal loss occurring in early phase of disease 
(Lindberg and Kappos, 2006). These evidences suggest a strong neurodegenerative component, 
which contributes to pathogenesis and reveal that MS may be an inflammatory demyelinating 
and neurodegenerative disease that affects all the CNS (Herz et al., 2010). One hallmark of MS 
are in fact demyelinated lesions in white matter related with axonal degeneration and immune 
cells infiltration. The focal demyelinated plaques, present in the grey and white matter at all 
stages of the disease, are infiltrated by populations of immune cells and immune mediators such 
as T cells, B cells, macrophages and microglia, as well as cytokines, chemokines and other toxic 
agents (Lassmann et al., 2012; Napoli and Neumann, 2010). The infiltration of immune cells is a 
consequence of BBB disruption, partly due to matrix metalloproteinases (MMPs). The 
expression of several MMPs, particularly MMP-2 and -9, are also altered in microglial cells of MS 
lesions (Könnecke and Bechmann, 2013; Rosenberg, 1995). 
Besides demyelination, immune cell-related inflammation is critical for neuronal 
damage due to pro-inflammatory neurotoxic substances release and consequent damaging 
processes. In these patients, the inflammatory lesions consist of perivascular and parenchymal 
infiltrates of lymphocytes and macrophages (Lassmann et al., 2012). While in active lesions, 
there are low levels of T cells at sites of the initial tissue injury, the ongoing tissue damage is 
associated with the infiltration of macrophages and the activation of resident microglia.  In 
addition, the brains of these patients also display global changes as widespread inflammation, 
microglial activation, astrocytic gliosis and slight demyelination and axonal loss in normal-
appearing white matter. These changes together with widespread loss of tissue volume 
observed in the cortex result in brain atrophy with ventricles dilatation (Herz et al., 2010; 
Lassmann et al., 2012). 
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1.3. Molecular mechanisms of neurodegeneration in Multiple Sclerosis 
As a result of inflammatory processes many molecular changes occur in CNS during MS, 
namely the secretion of neurotoxins that induce immune responses with important roles in 
homeostasis and neuronal metabolism. These responses have different functions depending on 
the time of exposure. At short-term, the immune response has a crucial role in tissue defense 
but, at long-term, immune cells induce stress responses (Friese et al., 2014). The molecular 
pathways involved in MS neurodegeneration are very complex due to the heterogeneity of this 
disease. Although most of these mechanisms are also associated with other neurodegenerative 
diseases, the extensive primary demyelination and preservation of axons is specific for MS. It is 
therefore necessary to understand the pathogenesis of MS and identify the mechanism that 
specifically affects myelin and the cells responsible for its production, contributing to 
widespread primary demyelination (Lassmann, 2013). After this first myelin destruction due to 
inflammation, other known mechanisms may be responsible for axonal loss, worsening MS 
clinical course. 
 
1.3.1. Free Radicals and Oxidative Stress 
Oxidative stress reflects an imbalance between the reactive oxygen species (ROS) 
production and the ability to detoxify this reactive species and repair the damage (Mao and 
Reddy, 2010). Although it cannot be generalized, there are evidences that in some patients with 
MS, oxidative stress may be the principal mechanism implicated in the pathogenesis of disease 
(van Horssen et al., 2008). 
Oxidative stress is able to damage the cells by promoting the oxidation of cellular 
components, as lipids, proteins and nucleic acids (mainly mitochondrial DNA, mtDNA), which 
consequently leads to cell death (Mao and Reddy, 2010). Specifically, it was verified an 
accumulation of oxidized DNA and lipids within lesions in all stages of the disease. However, in 
active lesions there is a greater indication of oxidative damage than in inactive lesions 
(predominate in the progressive stage of MS), which presents a low signal (Haider et al., 2011). 
As already described, the excessive inflammatory environment in demyelinating lesions 
is favorable to ROS and reactive nitrogen species (RNS) formation, and this increased levels of 
reactive species may compromise the antioxidant defenses in our organism, particularly in the 
lesions (Mao and Reddy, 2010). In support of these data, it was observed an increased 
expression of enzymes responsible for free radical production (e.g. myeloperoxidase, 
nicotinamide adenine dinucleotide phosphate oxidase, xanthine oxidase) in active lesions, 
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mainly in areas of initial tissue injury (Fischer et al., 2012). The presence of superoxide and 
peroxynitrite, which are produced due to ROS and RNS reaction, as well as the increased levels 
of DNA oxidation within plaques shows that the generation of reactive species may have an 
extremely toxic effect in neuronal and glial cells (Mao and Reddy, 2010). In support of these 
evidences, the presence of oxidized DNA and lipids in apoptotic oligodendrocytes and dystrophic 
axons also indicates the key role of ROS in demyelination and neurodegeneration (Lassmann et 
al., 2012). 
Despite the fact that anti-oxidative activity is not different in MS patients, comparatively 
with healthy controls, there are evidences that sulfhydryl groups, which have antioxidants 
properties, are decreased in MS patients (Mao and Reddy, 2010). However, some antioxidant 
enzymes (e.g. superoxide dismutases, catalase, peroxiredoxins) are upregulated in active MS 
lesions, which may indicate an active defense mechanism to reduce cellular damage caused by 
ROS (van Horssen et al., 2008). 
Oligodendrocytes are particularly sensitive to higher levels of these reactive species, 
comparatively with astrocytes and microglia. This fact may result from their reduced ability for 
antioxidant defense, rendering them more prone to oxidative stress toxicity which leads to 
oligodendrocyte death and consequent demyelination. Furthermore, ROS and RNS can also 
damage the own myelin sheath and promote its clearance by macrophages and microglia. In an 
early stage of MS, the oxidative stress appears to be triggered by activated microglia but, in a 
progressive stage, it may be intensified by further factors (Friese et al., 2014; Lassmann, 2013; 
Mao and Reddy, 2010). 
 
1.3.2. Mitochondrial dysfunction 
Mitochondria has as principal function to provide energy to cells in the form of ATP. It 
participates in many cellular processes, including fatty acid oxidation, apoptosis and calcium 
homeostasis. So, the high energy needed by CNS render it slightly vulnerable to mitochondrial 
damage. 
A serious consequence of high levels of ROS is mitochondrial dysfunction, which may 
result from different mechanisms. The released free radicals and modifying proteins can disrupt 
mitochondrial function by interfering with some components of respiratory chain and 
promoting mtDNA damage (Ellwardt and Zipp, 2014; Lassmann et al., 2012). These 
mitochondrial changes may explain pathological features of MS lesions as demyelination and 
remyelination impairment, destruction of thin-calibre axons, differentiation arrest of 
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oligodendrocyte progenitor cells, oligodendrocyte apoptosis and astrocyte dysfunction (Haider 
et al., 2011; Lassmann et al., 2012). 
Mitochondria plays several crucial functions in different pathways including oxidative 
energy metabolism, where the most of the ATP is synthesized. Therefore, it is easy to understand 
that the impairment of mitochondria, besides leading to the production of more reactive species 
that will exacerbate the tissue injury (Mao and Reddy, 2010), will also induce energy failure. 
Indeed, it is clear that mitochondrial injury and consequent energy failure is a very important 
factor that drives to MS tissue injury (Lu et al., 2000; Witte et al., 2010).  
The first evidence that the mitochondrial damage has some role in MS lesions 
demonstrated a compromised NADH dehydrogenase activity as well as an increase of complex 
IV activity within lesions (Lu et al., 2000). Active lesions show significant changes in proteins of 
the mitochondrial respiratory chain and, in addition, deletions in mitochondrial DNA are present 
in neurons, especially in the progressive stage of the disease. 
Concerning oligodendrocytes, the mitochondrial damage results on release of 
apoptosis-inducing factor (AIF), which translocates into the nucleus and induces DNA damage. 
With the damage, one polymerase (poly ADP-ribose polymerase) is activated in an attempt to 
repair the injury, however, this leads to further energy deficiency (Lassmann et al., 2012). 
There are also suggestions that activated microglia play an important function in 
mitochondrial dysfunction, namely in MS. Activated microglia are responsible for ROS and NO 
production that, besides damaging mtDNA, can lead to the inhibition of oxidative 
phosphorylation pathway disrupting the ATP production and increasing ROS formation (Witte et 
al., 2010, 2014). Additionally, there has been reported a reduction in PGC-1α (peroxisome 
proliferator-activates receptor gamma coactivator-1α), a transcriptional co-activator and 
regulator of mitochondrial function, in MS cortex. This decreased in PGC-1α levels coinciding 
with both reduced expression of subunits involved in oxidative phosphorylation pathway and 
decreased expression of several mitochondrial antioxidants (Witte et al., 2013). Therefore, 
mitochondria has a decreased capacity to produce ATP and detoxify oxidative stress, which can 
compromise its efficient functioning. 
 
1.3.3. Ion channel dysfunction 
The intracellular environment is very important for maintaining neuronal functions. 
Abnormal expression of Na+ channels, acid-sensing Na+ channels, glutamate receptors and 
voltage-gated Ca2+ channels has been detected in dystrophic and demyelinated axons. In this 
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context, the ion channel dysfunction has a great impact on neurons and axons, which might even 
lead to their degeneration and death in progressive phase of MS (Friese et al., 2014; Lassmann 
et al., 2012; Mao and Reddy, 2010). As already mentioned, in response to an inflammatory 
stimulus, energy imbalance and demyelination may lead to activation, dysfunction and altered 
distribution of ion channels, inducing downstream mechanisms. These mechanisms are mostly 
responsible for Ca2+ accumulation and apparently may be the promoters of neurotoxicity and 
trigger of innumerous enzymes activation, which compromise both the normal mitochondrial 
functioning and axonal transport and result in additional increase of Ca2+levels. Moreover, the 
wrong distribution of voltage-gated Ca2+ channels (VGCCs) in demyelinated fibers may lead to 
an abnormal influx of Ca2+, which contributes to axonal death (Friese et al., 2014). 
The Na+ channels are responsible for the acceleration of the saltatory conduction in 
myelinated axons, which is the propagation of an action potential from one node of Ranvier to 
another, along a myelinated fiber. When into the axon, Na+ is exchanged for K+ by Na+/K+-ATPase, 
and this ion exchange is important for axonal polarization. This enzyme is responsible for 
correcting Na+ and K+ levels and for preventing a pathological influx of Na+ in axons, however, in 
pathological conditions, inflammatory mediators are released and cause the Na+/K+-ATPase 
failure and consequent mitochondrial injury (Mao and Reddy, 2010). It has also been shown that 
under hypoxia, this Na+/K+ pump activity are inhibited and that reactive species increase its 
degradation (Waxman, 2008; Young et al., 2008). 
 
1.3.4. Excitotoxicity of Glutamate 
Glutamate has been found in MS lesions at high concentrations (Srinivasan et al., 2005). 
It is one of the most important excitatory neurotransmitter of the CNS and modulates ion 
homeostasis into the cells through several receptors including N-methyl-D-aspartate (NMDA) 
and α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)/kainate receptors. The 
glutamate-mediated excitotoxicity is an important connection between neuroinflammation and 
neurodegeneration, once high levels of glutamate stimulate its receptor and lead to 
deregulation in ion homeostasis contributing to neurotoxicity associated with axonal, 
oligodendroglial and myelin damage or even cell death (Ellwardt and Zipp, 2014; Takaki et al., 
2012). So, excessive levels of glutamate, which are released by activated immune cells including 
activated microglia, may contribute to the lesion development in MS by overstimulation of 
ionotropic receptors (Pitt et al., 2000). This involvement in lesion development is supported by 
results that demonstrate a reduction of neurological disability and axonal damage, and an 
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increase of oligodendrocyte survival with AMPA/kainate receptor antagonist treatment. Thus, 
these results show that AMPA/kainate-mediated glutamate excitotoxicity has an important role 
in CNS damage in the animal model of MS, the experimental autoimmune encephalomyelitis 
(EAE) and probably also in the course of MS (Pitt et al., 2000). 
Also the activation of microglia seem to be involved in the impairment of glutamate 
transporters. Domercq and collaborators showed that high ROS levels released by activated 
microglia inhibit glutamate uptake by oligodendrocytes, resulting in extracellular glutamate 
increase (Domercq et al., 2007). In addition, it has further been demonstrated that activated 
microglia are correlated with focal loss of excitatory amino acid transporters, EAAT1 and EAAT2. 
They also verified alterations in the mechanisms of glutamate uptake only in the presence of 
activated microglia (Vercellino et al., 2007). Once EAATs are fundamental in both the 
maintenance of low extracellular glutamate levels and in prevention of excitotoxicity as well, 
activated microglia appear to have an important role in excitotoxicity present in MS. 
 
1.3.5. Iron accumulation  
It is known that iron accumulates in healthy human brain with age increase. This fact 
may be relevant once progressive phase of MS usually starts between 40 and 50 years of age 
(Lassmann et al., 2012). 
Iron, which is mainly stored in oligodendrocytes, is crucial for normal brain metabolism, 
including for myelination, however, it may generate ROS (Friese et al., 2014; Hametner et al., 
2013). As consequence of oxidative stress, activated microglia release H2O2 that diffuses into 
oligodendrocytes with Fe2+ accumulation and forms toxic radicals leading to cell death. The Fe2+ 
released from these dying oligodendrocytes is taken up by microglial cells, which subsequently 
become dystrophic. These dystrophic microglia release more Fe2+ that results in more oxidative 
tissue injury. So, iron accumulation within oligodendrocytes is also a relevant mechanism that 
further contribute to neurodegeneration in MS (Ciccarelli et al., 2014; Lassmann et al., 2012). 
 
1.3.6. Inflammatory mediators 
Myelin sheaths loss occurs due to the migration of auto-reactive immune cells through 
the BBB that attack myelin components. Within the CNS, activated T-cells together with 
activated microglia, macrophages and astrocytes, release pro-inflammatory cytokines, creating 
a pro-inflammatory environment which can lead to neurodegeneration. The accumulation of 
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these pro-inflammatory mediators, which are described in section 1.4.1.2, amplify both 
inflammatory and immune response contributing to demyelination and then 
neurodegeneration  (Dendrou et al., 2015; Glass et al., 2010; Lassmann and van Horssen, 2011; 
Vogel et al., 2013). Besides all these inflammatory contributors, including high levels of S100B, 
the protein in which we are interested, stimulate the release of further inflammatory mediators, 
meaning that it has a function on exacerbating the inflammatory response (Bianchi et al., 2010; 
Villarreal et al., 2014). 
 
1.4. Microglia as cellular players in Multiple Sclerosis 
As mentioned above, in all phases of MS, active tissue injury is associated with 
inflammatory infiltrates. In addition, several immune cells including activated microglia are 
observed in lesions borders. These cells express cytokines and enzymes involved in the 
production of ROS and RNS (Fischer et al., 2012), having a crucial effect on MS pathogenesis. 
 
1.4.1. Microglial cells 
Microglia are the tissue macrophages of the brain and the main form of immune defense 
in the CNS constituting around 10% of the cells in this system. They are members of the innate 
immune system and respond to danger signals, initiating an acute inflammatory response, 
within the CNS (Goldmann and Prinz, 2013; Jack et al., 2005). These cells have functions similar 
to those of other tissue macrophages such as phagocytosis, antigen presentation and secretion 
of cytokines (Herz et al., 2010). Microglia act quickly after an insult in order to restrain the 
damage and promote recovery. However, besides promoting neuroprotection and stimulating 
tissue repair, activated microglial cells can exacerbate an inflammatory status and trigger 
neurotoxic pathways, which may lead to a progressive neurodegeneration (Correale, 2014). 
An important characteristic of microglia are their extensive branches, which allows that 
these cells continuously patrol the CNS parenchyma (Benarroch, 2013; Olah et al., 2011a). This 
characteristic makes microglial cells the first line of defense in CNS (Correale, 2014; Giunti et al., 
2014; Olah et al., 2011a). As consequence of brain injury, resident microglia change their 
surveillance phenotype to an “activated” morphology, which are associated with different 
phenotypes highly dependent on the type, intensity and duration of their exposure to stimuli 
(Benarroch, 2013; Correale, 2014; Perry et al., 2010). These different microglial phenotypes may 
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be defined based on morphological, molecular and functional characteristics (Kettenmann et al., 
2011). 
 
1.4.1.1. Surveillant microglia 
Under healthy conditions, microglial cells display a surveillant/patrol or M0 phenotype, 
which are characterized by a ramified morphology, a slow turnover rate and low expression of 
surface molecules. This apparently “quiescent” microglia are constantly scanning their 
environment for exogenous or endogenous signals (Giunti et al., 2014; Kettenmann et al., 2011), 
and are ready to rapidly switch to the “activated” state, after injury occurrence (Kettenmann et 
al., 2011). 
 Surveillant microglia phenotype seems to be preserved through interactions between 
some receptors and their respective ligands expressed in neurons, such as CD200-CD200R and 
fractalkine (CX3CL1)-CX3CR1, which are described as “off signals” (Correale, 2014; Jones and 
Lynch, 2014; Perry et al., 2010). A study that reveals the presence of a microglia mainly activated 
in CD200 knockout mice comparatively with control mice, clearly demonstrated the importance 
of these interactions in the surveillant phenotype (Hoek, 2000). Besides this, neurons are also 
responsible for several neurotrophic factors release (e.g. nerve growth factor and brain-derived 
neurotrophic factor) that keep the microglial cells at rest (Perry and Teeling, 2013). 
 
1.4.1.2. Activated microglia 
Any disturbance, which may indicate a potential danger to the CNS changes microglial 
morphology, gene expression and their functional behavior (Correale, 2014; Kettenmann et al., 
2011). Through their branches, microglia sense variations in their microenvironment, recognize 
danger signs and consequently become activated. Morphologically, microglia retract their 
branches changing their shape to an amoeboid form (Correale, 2014). Moreover, microglia 
become motile and go to the lesion following chemotactic gradients. In addition, CNS injury 
induces microglia proliferation that provide more cells for protection and repair of tissue 
homeostasis (Benarroch, 2013; Kettenmann et al., 2011). 
Besides all these alterations, microglia display molecular alterations such as 
upregulation of some surface markers and specific proteins, presenting a classically activated 
(M1) or an alternative activated (M2) phenotype (Chhor et al., 2013; Correale, 2014; Giunti et 
al., 2014; Goldmann and Prinz, 2013). M1 consists of a pro-inflammatory phenotype mainly 
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associated with cytotoxic response, which is responsible for mediating innate immune responses 
but also adaptive immune responses. The innate immune response may be triggered by 
damage-associated molecular patterns (DAMPs), misfolded proteins and other proteins 
released from injured neurons, which in turn activates toll-like receptors (TLR), in microglial cells. 
In response to this interaction, TLRs activate downstream signaling cascades leading to 
transcriptional activation of nuclear factor kappa-B (NF-KB) and subsequent acute inflammation. 
This feature is characterized by the production ROS, that leads to neuronal death, engagement 
of NLRP3 inflammasome, expression of altered enzymes and surface markers and release of pro-
inflammatory cytokines, as shown in Table I. 1 (Benarroch, 2013; Chhor et al., 2013; Correale, 
2014; Goldmann and Prinz, 2013). The activation of inflammasome by DAMPs enhances the 
inflammatory response. Also the high-mobility group box 1 (HMGB1), a protein that is secreted 
by damage neurons for signaling the cell damage, can interact with TLRs, among others, further 
activating microglia and exacerbating the NF-KB signaling cascade (Brites and Vaz, 2014). 
Additionally, the adaptive immune response is triggered by interferon gamma, which is released 
from T helper cells type 1 (Th1), and in response to that, microglia become antigen-presenting 
cells and release pro-inflammatory mediators as effectors of adaptive immunity (Benarroch, 
2013). 
 
Table I. 1. Characteristics of different microglial phenotypes (compiled from Brites and Vaz, 2014; Correale, 2014; 
David and Kroner, 2011; Liu et al., 2008) 
Phenotype 
Inflammatory 
mediators released 
Phenotypic markers 
Classically activated 
microglia, M1 
- Tumor necrosis factor 
alpha (TNF-α) 
- Interleukin (IL)-1β 
- IL-6 
- Milk fat globule factor-
E8 (MFG-E8) 
- Inducible nitric oxide synthase (iNOS) 
- Cluster of differentiation 45 (CD45) 
- CD86 
- Major histocompatibility complex, 
class II (MHC-II) 
Alternative activated 
microglia, M2a 
- IL-10 
- Transforming growth 
factor-beta (TGF-β)  
- Arginase 1 (Arg1) 
- Resistin-like molecule alpha or 
protein found in inflammatory zone 
(FIZZ-1) 
- Suppressor of cytokine signaling 1 
(SOCS-1) 
Immunoregulatory, 
M2b 
- IL-10 
- TNF-α 
- IL-1β 
- IL-6 
- SOCS-3 
Acquired-deactivating, 
M2c 
- IL-10 
- TGF-β 
- MFG-E8 
- Arg1 
- SOCS-3 
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M2 microglia phenotype plays a crucial role in repair and healing of tissues, once 
microglia secrete extracellular matrix proteins and growth factors, and promote phagocytosis of 
cellular and myelin debris contributing for the remyelination process. Moreover, these microglia 
are also known for their involvement in synapse repair and remodeling (Correale, 2014). M2 
microglial phenotype is induced by signals from apoptotic cells, as heat shock protein 60 
(Hsp60), that activates triggering receptor in myeloid cells-2 (TREM-2), or by anti-inflammatory 
cytokines such as interleukin (IL)- 4 and IL-13, which are released from Th2 helper cells 
(Benarroch, 2013; Olah et al., 2011b). Thus, this phenotype seems to be beneficial compared 
with M1 however, a prolonged activation of this M2 phenotype may be harmful for preventing 
axonal growth (Brites and Vaz, 2014). In addition, there are three different subclasses of M2 
microglia, M2a, M2b and M2c, which are induced through polarizing signals and have different 
functional properties. M2a is an alternative activation repair/remodeling phenotype, which is 
recruited for phagocytosis and inﬂammation repair and induced by IL-4 and IL-13, and express 
specific markers, as presented in Table I. 1 (Brites and Vaz, 2014; Chhor et al., 2013; Varnum and 
Ikezu, 2012). Moreover, M2a microglia release anti-inflammatory mediators that trigger an anti-
inflammatory response and promote tissue repair (Correale, 2014; Goldmann and Prinz, 2013). 
The immunoregulatory or M2b phenotype is stimulated through immune complexes, TLR 
agonists and IL-1R ligands. Although M2b microglia release IL-10, an anti-inflammatory cytokine, 
they also release some pro-inflammatory cytokines (Table I. 1), which suggests that M2b 
microglial cells may act in and modulate different conditions of inflammation (Chhor et al., 2013; 
David and Kroner, 2011). The specific markers of M2b phenotype are SOCS-3 and IL-1R 
antagonist (IL-1Ra) (Chhor et al., 2013). The acquired-deactivating or M2c phenotype is induced 
by IL-10, TGF-β, glucocorticoids and enhances anti-inflammatory marker expression (Table I. 1) 
while decreasing pro-inflammatory cytokine levels (Chhor et al., 2013; Varnum and Ikezu, 2012). 
Besides modulating the anti-inflammatory polarization through the downregulation of pro-
inflammatory markers, SOCS-1 also regulates M2 phenotype, since the expression of SOCS-1 is 
increased in M2 phenotype (Davey et al., 2006; Guedes et al., 2013; Wilson, 2014). 
As already mentioned, an important neuroprotective function of microglial cells is 
phagocytosis. M1 and M2c microglia can produce MFG-E8 that recognizes the 
phosphatidylserine (PS) exteriorized by apoptotic cells and triggers a signaling cascade that 
stimulates the phagocytic process of dying cells (Brites and Vaz, 2014). 
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1.4.1.3. Microglia in MS 
The role of microglia in MS is controversial. Several evidences indicate that classically 
activated microglia promotes neuroinflammation and demyelination in MS and in EAE, 
contributing to CNS injury. To elucidate the function of microglial cells, it has been shown that 
the inhibition of microglial activation results in a delayed EAE onset (Bogie et al., 2014; Giunti et 
al., 2014; Heppner et al., 2005). In addition, microglial activation has been observed in post-
mortem brain tissue of MS patients as well as the presence of clusters of activated microglia 
within the normal-appearing white matter (Giunti et al., 2014; van Horssen et al., 2012). Our 
group also observed a large population of activated microglia/macrophages and PLP-positive 
macrophages in active MS lesions in contrast to chronic MS lesions (Barateiro et al., 2015) 
(Figure I. 2). 
 
 
Figure I. 2. Presence of microglia in active (A) or chronic (B) MS lesions. Frozen sections of autopsied brain samples 
of MS patients were immunostained for PLP to detect white matter and for HLA-DR MHC class II clone LN3 to detect 
macrophages/microglial cells. (A) Active MS lesions were outlined by PLP staining and LN3 immunoreactivity. 
Magnification ×43. In contrast, (B) chronic MS lesions showed decreased PLP and LN3 immunostaining. Magnification 
×43. (Adapted from Barateiro et al., 2015). 
 
However, all activation states of microglia may be present in disease indicating that 
there are multiple populations of microglia occurring in the course of a demyelinating episode 
(Goldmann and Prinz, 2013). Thus, microglia can also present an alternative activated phenotype 
in EAE or MS, with the ability to phagocyte apoptotic cells and myelin debris, a crucial step for 
tissue regeneration. In this context, the role of TREM-2, a phagocytic stimulator, was evaluated 
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and it has been demonstrated that this receptor is upregulated in EAE, facilitating the debris 
clearance. Moreover, its blockade results into EAE exacerbation with more infiltrates and 
demyelination in the parenchyma (Piccio et al., 2007). 
A study that evaluated the role of microglia/macrophages polarization in remyelination 
showed that a switch from an M1- to an M2-phenotype is essential for the remyelination 
process. Particularly, they observed that this change occurs at the time of oligodendrocytes 
differentiation from oligodendrocyte progenitor cells, which have been recruited into the lesion. 
Thus, they demonstrated that M2 microglia are necessary for oligodendrocyte differentiation 
and maturation, which are very important for the efficient remyelination (Miron et al., 2013). 
Given that microglial cells present distinct roles along disease progression, it is 
important to understand how they exert a beneficial role in MS with the objective to modulate 
this reactivity to a more neuroprotective phenotype during the course of the disease. 
 
2. S100B 
S100 proteins are part of a low-molecular-weight and acidic proteins family that are 
known to contain two distinct EF-hand helix-loop-helix calcium-binding sites (Donato et al., 
2013). This family is subdivided into three subgroups according to their action: (i) only exert 
intracellular regulatory effects, (ii) have intracellular and extracellular functions, or (iii) play 
extracellular regulatory effects (Donato et al., 2013). S100B is a 10.5 kDa member of this family, 
with both intracellular and extracellular functions, that is expressed in some cell types from 
different tissues and that appears to be expressed at highest levels, in the CNS, namely by glial 
cells (Adami et al., 2001; Michetti et al., 2012). Usually, this protein exists within cells as a 
homodimer but it can also form heterocomplexes when associated with S100A1 monomer 
(Donato et al., 2009). 
Due to important functions that S100B presents in proliferation, migration, 
differentiation and apoptosis, it plays a critical role during brain development acting as a 
neurotrophic factor, by furthering neurite outgrowth and neuronal survival for low/physiological 
levels (nM) (Donato et al., 2013; Koppal et al., 2001). 
On the other hand, it was also demonstrated that S100B expression is increased in many 
tumors as well as in the aging brain and in the brain of patients affected by different pathologies 
as Alzheimer's disease, HIV infection, chronic epilepsy and other brain pathological conditions 
as MS (Donato et al., 2009; Hein Née Maier et al., 2008). Once these high concentrations of 
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S100B are present in several brain pathologies, this protein may be considered a biomarker of 
brain damage (Donato et al., 2013). 
 
2.1. Dual role of S100B in physiology and pathology 
As mentioned above, S100B is a Ca2+ sensor, so, upon binding to Ca2+, S100B changes its 
conformation leading to hydrophobic patch exposure to the solvent and its interaction with 
target proteins (Sorci et al., 2013). Several of these target proteins have been already identified 
and its interaction with S100B is involved in important intracellular processes (Table I. 2). 
Accordingly, S100B acts as a stimulator of proliferation and migration as well as an inhibitor of 
apoptosis and differentiation. Moreover, S100B is involved in the regulation of energy 
metabolism, transcription, and protein phosphorylation, as well as in Ca2+ homeostasis (Donato 
et al., 2009; Sorci et al., 2010). 
It is known that astrocytes are the main cell type in CNS that express and secrete S100B, 
however, other S100B-expressing cells can release the protein in case of damage or necrosis 
(Sorci et al., 2010). Therefore, besides having a regulatory function within the cytoplasm where 
it is expressed, S100B can act as a signal molecule in extracellular space given that it can be 
released by damaged cells (Rustandi et al., 2000; Shashoua et al., 1984; Sorci et al., 2010). Once 
released, S100B may have a beneficial or harmful action. There are evidences that this release 
may be mostly dependent on the presence and activation of its receptor RAGE (Receptor for 
Advanced Glycation Endproducts), which engagement may stimulate further S100B release 
(Donato et al., 2009; Sorci et al., 2013). 
RAGE is a member of the immunoglobulin-like cell surface receptor superfamily 
composed by a cytosolic domain responsible for signal transduction, a transmembrane domain 
which anchors it in the membrane, a variable binding-domain and two constant domains 
(Ostendorp et al., 2007; Sparvero et al., 2009). This receptor is able to transduce inflammatory 
stimuli and the effects of neurotrophic and neurotoxic factors and therefore, S100B emerged as 
a damage-associated protein that regulate inflammation-related events and play a role in 
pathophysiology of neurodegenerative disorders and inflammatory brain diseases (Bianchi et 
al., 2011; Donato et al., 2013; Zhang et al., 2011b). 
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Table I. 2. S100B target proteins involved in intracellular processes (adapted from Donato et al., 2013) 
Intracellular Function Target Protein 
Ca2+ homeostasis 
- AHNAK 
- Annexin 6 
Cell locomotion 
- Src/PI3-K/RhoA/ROCK 
- Src/PI3-K/Akt/GSK3β/Rac1 
Cell proliferation and 
differentiation 
- p53 
- PI3-K/Akt/p21WAF1/cdk4/Rb/E2F 
- IKKβ/NF-KB 
Channel Activity -      EAG1 K+ 
Cytoskeleton 
- Microtubules 
- Type III intermediate filaments 
- Caldesmon 
- Calponin 
- IQGAP1 
Enzymes 
- Membrane-bound GC 
- Fructose-1,6-biphosphate aldolase 
- Phosphoglucomutase 
- Twichin 
- Ndr 
- Src 
Protein degradation - E3 ligase hdm2 
Protein phosphorylation 
- p53 
- τ proteins 
- GAP43 
- p80 
- GFAP 
- Vimentin 
Receptor function - D2 receptor/ERK1/2/adenyl cyclase 
Transcription factors - p53 
 
Besides having different functional roles, the extracellular form of S100B, which has 
more effects in CNS, presents different effects on neurons, astrocytes and microglia, depending 
on the concentration (Donato et al., 2013). At physiological levels the protein displays trophic 
effects on neurons promoting neuron survival and growth as well as microglia quiescence, 
although high concentration of S100B display pro-inflammatory effects and activate pro-
apoptotic pathways (Reali et al., 2005). In particular, high levels of S100B can stimulate the nitric 
oxide synthesis by astrocytes and microglia leading to neuronal and astrocyte apoptosis. 
Moreover, high S100B stimulates the release of cytokines contributing to brain inflammatory 
response (Bianchi et al., 2011).  
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2.1.1. Extracellular S100B effect on microglial cells 
The high expression levels of S100B are normally associated to astrogliosis in the course 
of neurodegenerative diseases. These levels might be the result of neuronal and glial cells 
pathology given that the protein is released by damaged oligodendroglial or astroglial cells, 
which have will then activate microglial cells responsible for the innate immune response (Sorci 
et al., 2010). However, expression levels of S100B exerts two different roles in microglia 
depending on concentration. 
At physiological concentrations, S100B can prevent microglia activation via STAT3 
pathway and may also act as a signaling trophic protein that promotes a more protective 
phenotype of microglia (Zhang et al., 2011b). On the other hand, high S100B concentrations, in 
the presence of bacterial endotoxin or interferon-γ (IFN-γ), play a main role on microglia 
activation, exacerbating brain inflammatory response. This activation was shown to be mediated 
by stimulation of iNOS leading to an increase of nitric oxide release (Adami et al., 2001; Bianchi 
et al., 2007). 
In addition, there is an evidence that S100B stimulates the microglia migration via RAGE-
dependent mechanism. It was demonstrated that once S100B accumulates in the extracellular 
space after brain damage, the increased S100B levels might contribute to intensify the 
inflammatory response by activating microglia and stimulating their migration (Bianchi et al., 
2011). 
 
2.2. S100B in MS 
Increased S100B levels were first detected in cerebrospinal fluid (CSF) of MS patients 
(Michetti et al., 1979). Another study revealed that S100B levels in CSF were higher in patients 
with RRMS than in patients with SPMS (Bartosik-Psujek et al., 2011). We confirmed that both in 
CSF and in serum samples from RRMS patients there is a significant increase of S100B production 
at the time of diagnosis (Barateiro et al., 2015). S100B increase may exacerbate the release of 
inflammatory mediators and subsequently contribute to neuronal death (Hu et al., 1996). These 
results indicate S100B as a potential biomarker for MS diagnosis and prognosis, possibly helping 
to distinguish between relapsing remitting and progressive phases of MS. 
One study reported the presence of S100B in acute lesions of post-mortem brain tissue 
of patients with RRMS (Petzold et al., 2002). In similar samples, our recent work demonstrated 
that S100B is overexpressed both in active and chronic lesions, mainly by astrocytes (Figure I. 3). 
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In addition, it showed that in chronic lesions S100B is still diffusely expressed into the 
demyelinated area (Barateiro et al., 2015). Interestingly, those active MS lesions also showed an 
increase of RAGE expression that co-localized with microglia/macrophages cells, while almost 
no RAGE was found in chronic lesions that are almost depleted of microglia/macrophages 
(Figure I. 3). 
 
 
Figure I. 3. Expression of S100B and its receptor RAGE in active (A) and chronic (B) MS lesions. Frozen sections of 
autopsied brain samples of MS patients were immunostained for S100B and RAGE. (A) S100B and its receptor RAGE 
are markedly expressed in active MS lesions by astrocytes and activated macrophages/microglia, respectively. 
Magnification x40. Insets show the co-localization of (I) glial fibrillary acidic protein (GFAP, red), an astrocytic marker, 
with S100B (green) and the co-localization of (II) LN3 (red), a marker of activated macrophages/microglia with RAGE 
(green). Magnification x63. (B) S100B but not RAGE is continuously expressed in chronic MS lesions. Magnification 
x40. (Adapted from Barateiro et al., 2015). 
 
Given the increased expression of S100B during MS episodes, the role of S100B in 
different neurodegenerative diseases and its apparent involvement in microglia activation, it is 
of utmost importance to assess whether by modulation of S100B function it is possible to change 
the reactivity of microglia to a more neuroprotective phenotype during the course of MS. 
 
3. Experimental models to study MS pathophysiology 
Failure to understand the neurodegenerative mechanisms involved in MS and 
therapeutic inefficacy of diverse treatments led to development of multiple experimental 
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models that mimic the hallmarks of the disease. However, the complexity of MS still hinders the 
development of the perfect model for this disease (Murta and Ferrari, 2013). 
The EAE, a model characterized by inflammation, demyelination and 
neurodegeneration, is one of the most widely used in vivo model to study MS that involves the 
immunization of genetically susceptible animals with a myelin protein inducing brain 
inflammation and destruction of myelin. However, EAE models fail to expect the clinical efficacy 
in patients (Mathew et al., 2013; Ransohoff, 2012). Moreover, in vivo models entail an expensive 
cost, as well as ethical problems and, therefore, alternative models should be used whenever 
possible. 
For decades, organotypic slice cultures were used in CNS research due to three-
dimensional architecture, maintenance of contact between different cells and the presence of 
all the cells of CNS which play a key role in lesion recovery (Denic et al., 2011; Gähwiler, 1984). 
Organotypic slice culture is a more complex model to study cell-cell interactions, being named 
ex vivo, and can be prepared from different brain regions, such as cerebellum, hippocampus, 
striatum, cortex and spinal cord, (Birgbauer et al., 2004; Gähwiler, 1984; Stoppini et al., 1991). 
The preferential region used in MS research, compared with other CNS regions is cerebellum 
due to the abundance of white matter and the well-known pattern of myelin tracts (Zhang et 
al., 2011a). 
This method was initially used for electrophysiological studies, in 1941, but the process 
of myelination was only reported in 1956, in cerebellar slices (Hild, 1956; Levi and Meyer, 1941). 
In 2004, lysophosphatidylcholine (LPC) was used to demyelinate rat cerebellar slices, which was 
followed by the reappearance of myelin sheaths, suggesting remyelination (Birgbauer et al., 
2004). Thus, LPC can be used as a good molecule to induce demyelination in cerebellar 
organotypic slice cultures (COSC), providing a model that allows the study of demyelination and 
remyelination in an ex vivo model. This model offers advantages compared with other in vitro 
models, once it can mimic the multicellular complexity as well as the structure and functionality 
of in vivo conditions (Cho et al., 2007). Besides preserving glial cells contribution into 
myelination-associated processes, organotypic slice model excludes the systemic immune 
system interactions that would render the model more complex (Miron et al., 2010). Thus, this 
ex vivo model is an attractive proposal for MS study and the assay of potential new therapeutic 
strategies. 
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3.1. Novel findings on the role of S100B in the ex vivo demyelinated model 
Recently, our group showed that S100B is highly released upon LPC-induced 
demyelination in COSC (Figure I. 4), mostly by astrocytes, in parallel to a massive gliosis 
(Barateiro et al., 2015). 
 
 
Figure I. 4. S100B is markedly released upon LPC-induced demyelination of cerebellar organotypic slice cultures. 
Cerebellar organotypic slice cultures were exposed to LPC at 7 days in vitro during 18 h and allowed to recover for 30 
h. Samples for detection of S100B secretion were collected before the incubation (0 h), at 18 h post-incubation with 
LPC and at 48 h, i.e. after 30 h of recovery. Results are mean ± SEM. ***p<0.001 vs. Control. (Adapted from Barateiro 
et al., 2015). 
 
Curiously, when S100B was therapeutically neutralized using a specific antibody, we 
could observe a reduced demyelination (Figure I. 5), as well as reduced astrogliosis. 
Nevertheless, although the density of microglia in the slice showed no apparent differences 
upon anti-S100B co-treatment, the release of cytokines was markedly reduced suggesting a 
potential inhibition of microglia pro-inflammatory response (Barateiro et al., 2015). 
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Figure I. 5. Blockade of S100B following demyelination partially prevents loss of myelinated fibers. Cerebellar 
organotypic slice cultures were exposed to LPC at 7 days in vitro during 18 h and allowed to recover for 30 h. Slices 
were double immunostained with neurofilament-200 (NF-200), MBP and DAPI antibodies. (A) Confocal images are 
shown. Scale bar represents 100 μm. (B) Quantification of axon integrity was taken by averaging the area occupied 
by NF-200 staining for each stack. (C) The percentage of myelinated fibers was calculated by the ratio between the 
area of co-localization of NF-200 and MBP and the total area occupied by NF-200. Results are mean ± SEM. **p<0.01 
vs. Control; ##p<0.01 vs. LPC. (Adapted from Barateiro et al., 2015). 
 
So, in preliminary studies we explored the distribution of microglia along the slice. 
Usually in COSC microglia is distributed along the slice while myelin is found on the top of it. As 
shown in Figure I. 6, LPC-induced demyelination markedly increase microglia density, namely at 
the bottom of the slice. However, co-incubation of LPC and anti-S100B, although not preventing 
the increase of Iba-1 staining, suggest a more evident microglia in the region with highest 
amount of myelin debris (Figure I. 5). These images suggest that activated microglia moved to 
myelin surrounds when S100B was blocked, possibly increasing the phagocytosis of myelin 
debris which is crucial for further remyelination (Afonso, 2014). Since there are recent evidences 
that microglia switch from a cytotoxic to a protector phenotype during remyelination initiation 
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(Miron et al., 2013), it would be interest to evaluate if we can accelerate this change of microglia 
phenotype by neutralizing excessive S100B in the milieu and only preserving it physiological low 
concentration. 
 
 
Figure I. 6. Blockade of S100B following demyelination apparently induces microglia migration near to myelin 
debris. Cerebellar organotypic slice cultures were exposed to LPC at 7 days in vitro, in presence or absence of S100B 
antibody, during 18 h and allowed to recover for 30 h. Slices are incubated with Iba-1 and MBP antibodies and 
analyzed by immunohistochemistry. (Adapted from Afonso V MS thesis). 
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4. Aims 
The principal aim of this work is to evaluate the role of S100B in microglial response 
during MS. More specifically, we want to understand whether we may promote a more 
neuroprotective microglia phenotype, during the course of MS, through the modulation of 
S100B levels. 
Therefore, in order to display how S100B modulates microglial reactivity in an ex vivo 
model of demyelination, we will assess (i) the effect of S100B in microglia phenotype-related 
cell surface receptors; (ii) the role of S100B in microglia phenotype-related markers and (iii) the 
importance of S100B in microglia phagocytic ability. 
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II. Material and Methods 
1. Animals 
CD1 mouse pups were acquired from Instituto Gulbenkian de Ciência (IGC, Lisboa, 
Portugal). Animal care followed the recommendations of European Convention for the 
Protection of Vertebrate Animals Used for Experimental and Other Scientific Purposes (Council 
Directive 86/609/EEC) and National Law 1005/92 (rules for protection of experimental animals). 
All animal procedures were approved by the Institutional Animal Care and Use Committee. All 
efforts were made to minimize animal suffering and to reduce the number of animals used in 
order to use alternatives procedures to in vivo. 
 
2. Cerebellar Organotypic Slice Cultures (COSC) and its Treatment 
Cerebellum parasagittal slices were obtained from postnatal day 10 (P10) CD1 mouse 
pups. Briefly, after mice decapitation, the cerebellums were isolated from brains and 400 µm 
sagittal slices obtained using a Mcllwain tissue chopper. Four slices of different animals were 
transferred into membrane culture inserts (BD Falcon, #353493, Lincoln Park, NJ, USA) in 6-well 
cell culture plates that contain 1 mL of medium in per well and kept at 37°C, in 5% CO2 
conditioned atmosphere. Half media was replaced every day and slices were maintained for 7 
days in vitro (DIV) before treatment, to allow the clearance of debris and full myelination 
(Birgbauer et al., 2004). The culture medium consisted of 50% minimal essential media (MEM), 
(Gibco, Life Technologies, Inc., Grand Islands, USA), 25% of both heat-inactivated horse serum 
(Gibco) and Earle’s balanced salt solution (EBSS, Gibco), 6.5 mg/mL glucose, 25mM HEPES 
(Biochrom AG, Berlin, Germany), 1% of L-glutamine (Sigma-Aldrich, St. Louis, MO, USA) and 1% 
of antibiotic-antimycotic (Sigma-Aldrich). After 3 DIV, slice culture media was totally changed by 
a serum-free media that consists of Neurobasal-A (Gibco) supplemented with 2% B-27 (Gibco), 
2 mM L-glutamine, 36 mM glucose, 1% of antibiotic-antimycotic and 25 mM HEPES.  
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After 7 DIV, culture media was removed and slices were incubated with 0.5 mg/mL LPC 
in serum-free culture media, during 18h, at 37°C. To evaluate how S100B modulates the 
microglial reactivity, some slices were also incubated with LPC in the presence of anti-S100B 
antibody (1:500, AbCam, Cambridge, UK). Additionally, to assess the effect of the presence of 
an antibody we also incubated the slices with a control IgG (1:500, Santa Cruz Biotechnology, 
CA, USA). After incubation, the LPC-containing medium was removed and the slices were 
maintained in fresh medium or in medium supplemented with anti-S100B antibody or IgG during 
30h. Following these 30h, slices were: (i) stored in TRIzol® reagent, at -20°C, for RNA extraction; 
(ii) incubated with ice-cold cell lysis buffer (radio-immunoprecipitation assay buffer – RIPA), for 
protein extraction; (iii) dissociated and stained with specific antibodies for flow cytometry 
analysis; (iv) incubated with 1 µm fluorescent latex beads (1:100, Sigma Chemical Co., St. Louis, 
MO, USA) during 1h, at 37°C, for phagocytic studies; or (v) fixed in 4% paraformaldehyde (PFA) 
for immunohistochemistry assays. All supernatants were collected both before and after 
incubation with LPC. 
 
3. Total RNA Extraction, Reverse Transcription, Semi-quantitative 
RealTime Polymerase Chain Reaction 
For the determination of expression levels of diverse genes of interest, total cytoplasmic 
RNA was isolated from treated slices using the TRIzol® reagent method in accordance with the 
manufacturer’s guidelines (Invitrogen, Carlsbad, CA, USA) and RNA concentration was quantified 
using Nanodrop ND-100 Spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA). 
Aliquots of 500 ng of total RNA were reversely transcribed using the SensiFAST cDNA Synthesis 
Kit (Bioline), under manufacturer’s instructions. Semi quantitative (q)RealTime-PCR was 
performed on a RealTime PCR detection system (Applied Biosystems 7300 Fast RealTime PCR 
System, Applied Biosystem, Madrid, Spain) using a SensiFAST SYBR® Hi-Rox Kit (Bioline), under 
optimized conditions: 50°C for 2 min, 95°C for 2 min followed by 40 cycles at 95°C for 5 s and 
62°C for 30 s. In order to verify the specificity of the amplification, a melt-curve analysis was 
performed immediately after the amplification protocol (95°C for 15 s, followed by 60ºC for 30 
s and 95°C for 15 s). The PCR was performed in 96-well plates with each sample performed in 
duplicate, and a non-template control was included for each gene. The sequences used as 
primers are listed in the Table II.  1. 
Relative mRNA concentrations were calculated using the Pfaffl modification of the ΔΔCT 
equation, where CT is the cycle number at which fluorescence passes the threshold level of 
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detection, taking into account the efficiencies of individual genes. The results were normalized 
to the housekeeping gene β-actin in the same sample and the initial amount of the template of 
each trial was determined as relative expression by the formula 2-ΔΔCT. ΔCT is the value obtained 
for each sample by performing the difference between the mean CT value of each gene of 
interest and the mean CT value of β-actin. ΔΔCT of one sample is the difference between its ΔCT 
value and the ΔCT of the sample chosen as reference. 
 
Table II.  1. Primers used for qRealTime PCR 
Gene Forward Reverse 
Arg1 cttggcttgcttcggaactc ggagaaggcgtttgcttagttc 
β-actin gctccggcatgtgcaa aggatcttcatgaggtagt 
CEBP-α agcttacaacaggccaggtttc cggctggcgacatacagtac 
CX3CL1 ctcacgaatcccagtggctt tttctccttcgggtcagcac 
CX3CR1 tcgtcttcacgttcggtctg ctcaaggccaggttcaggag 
FIZZ-1 gccaggtcctggaacctttc ggagcagggagatgcagatgag 
HMGB1 ctcagagaggtggaagaccatgt gggatgtaggttttcatttctctttc 
IL-1β caggctccgagatgaacaac ggtggagagctttcagctcata 
IL-6 ccggagaggagacttcacag ggaaattggggtaggaagga 
IL-18 tggttccatgctttctggactcct ttcctgggccaagaggaagtg 
iNOS acccacatctggcagaatgag agccatgacctttcgcattag 
MBP ccatccaagaagaccccaca cccctgtcaccgctaaagaa 
MHC-II tgggcaccatcttcatcattc ggtcacccagcacaccactt 
NLRP3 tgctcttcactgctatcaagccct acaagcctttgctccagaccctat 
SOCS-1 caccttcttggtgcgcg aagccatcttcacgctgagc 
TGF-β cagagctgcgcttgcagag gtcagcagccggttaccaag 
TLR2 tgctttcctgctgaagattt tgtaccgcaacagcttcagg 
TLR4 acctggctggtttacacgtc gtgccagagacattgcagaa 
TNF-α tactgaacttcggggtgattggtcc cagccttgtcccttgaagagaacc 
 
 
4. Protein Extraction and Western Blot 
For the determination of cellular protein content, proteins were obtained by lysing cells 
in ice-cold cell lysis RIPA buffer, followed by sonication and centrifugation at 12,000 g for 10 min. 
Total protein concentrations were always measured using the Bradford method with Bio-Rad’s 
Protein Assay Reagent (BioRad Laboratories, Hercules, CA, USA). 
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Protein samples were separated on a 15% sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis (SDS-PAGE) and transferred to a nitrocellulose membrane (Amersham 
Biosciences, Piscataway, NJ, USA). Membranes were incubated in blocking buffer [Tween 20 
(0.1%)-Tris buffered saline, T-TBS, plus 5% (w/v) non-fat dried milk] at room temperature during 
1 hour and, after blocking, they were incubated overnight at 4°C, with primary antibodies (Table 
II.  2), diluted in T-TBS with 5% BSA. After three washes with T-TBS, the membranes were 
incubated at room temperature during 1 hour with respective secondary antibodies, specified 
in Table II.  3, diluted in blocking solution. After washing membranes with T-TBS, 
chemiluminescent detection was performed using LumiGLO® reagent (Cell Signalling, Beverly, 
MA, USA), bands were visualized in Chemidoc equipment and relative intensities of protein 
bands were analyzed using the Image Lab analysis software, both from Bio-Rad Laboratories 
(Hercules, CA, USA). The results were normalized to the housekeeping protein β-actin. 
 
Table II.  2. Primary antibodies used for immunoblot assays 
Antibody Host Brand Reference Number Dilution 
β-actin Mouse Sigma-Aldrich A5441 1:5000 
HMGB1 Mouse BioLegend 651402 1:100 
TLR4 Rabbit Santa Cruz Biotechnology sc-10741 1:100 
 
Table II.  3. Secondary antibodies used for immunoblot assays 
Antibody Brand Reference Number Dilution 
Horseradish-peroxidase-
conjugated anti-mouse 
Santa Cruz 
Biotechnology 
sc-2032 1:5000 
Horseradish-peroxidase-
conjugated anti-rabbit 
Santa Cruz 
Biotechnology 
sc-2004 1:5000 
 
5. Flow Cytometry – Fluorescence-activated cell sorting 
Slices were collected and incubated with 100 mg/mL of collagenase (1:100) during 10 
min, at 37°C, with agitation. Then, slices were dissociated and cell suspension made in flow 
buffer (PBS plus 2% FBS and 0.02% sodium azide). To prevent non-specific binding, cells were 
incubated for 20 min with CD16/CD32 (1:100) to block Fc receptors, at 4°C. After, cell suspension 
was incubated with the fluorescent labeled antibodies CD11b PerCp-Cy5, F4/80 FITC, CD45 PE 
and CD86 Bio-SAV PE for 30 min, at 4°C (1:100). Following the incubation, cells were washed 
with flow buffer, incubated with streptavidin (1:100) for the CD86 Bio-SAV PE antibody during 
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30 min, and then resuspended in flow buffer. Expression of surface antigens was measured using 
the BD FACSCalibur flow cytometer and data analyzed using the FlowJo software. 
 
6. Immunostaining procedure for phagocytic analysis 
For immunostaining procedure, insert membranes, which contain the fixed slices, were 
cut, placed into a cover glass and blocked with 1nM HEPES, 2% heat-inactivated horse serum, 
10% heat-inactivated goat serum (Biochrom), 1% bovine serum albumin (BSA, Sigma-Aldrich) 
and 0.25% Triton X-100 (Roche Diagnostics, Indianapolis, USA) in Hank’s balanced salt solution 
(HBSS, Gibco) for three hours, at room temperature. After blocking, slices were incubated with 
primary antibody (Iba-1, 1:250, Wako) diluted in the blocking solution, for 24h, at 4°C. After 
incubation, slices were washed three times for 15 min each with 0.01% Triton X-100 in PBS (T-
PBS) and incubated with secondary antibody (Alexa 594 anti-rabbit, 1:1000 Invitrogen) in 
blocking solution, for 24 h, at 4°C. Slices were then washed three times for 15 min each with T-
PBS, incubated with DAPI (1:1000, 3 min), washed three times for 15 min each with T-PBS and 
mounted using Fluoromount-G (Southern Biotech, Birmingham, AL) for confocal microscopy. 
Fluorescent images were acquired using a Leica DM6000 inverted microscope and analyzed with 
ImageJ soſtware. For each image were determined the total number of phagocyting cells and 
the total number of internalized beads.  
 
7. Statistical analysis 
Results are presented as mean ± SEM. Differences between groups were determined by 
one-way ANOVA using GraphPad PRISM 5.0 (GraphPad Software, San Diego, CA, USA), as 
appropriate. The p-values lower than 0.05 were considered as being statistically significant. 
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III. Results 
 
1. Myelin-related protein expression is recovered after S100B blockage 
Knowing that myelin-related MBP is an important constituent of myelin sheaths and to 
show that our ex vivo model is a good model to study demyelinated lesions, we decided to 
evaluate the gene expression of this protein extracted from COSC at 48 h post-incubation with 
LPC, by qRealTime PCR, using specific primers. 
As illustrated in Figure III. 1, LPC insult promoted a significant decrease in MBP and PLP 
expression (0.36-fold, p<0.001). Interestingly, co-incubation with anti-S100B antibody markedly 
prevented this MBP reduction (~80%, p<0.001), while the co-treatment with IgG did not 
significantly changed MBP mRNA expression. 
 
Figure III. 1. S100B neutralization attenuates demyelination induced by LPC. Cerebellar organotypic slice cultures 
were exposed to LPC at 7 days in vitro, in presence or absence of S100B and IgG antibodies, during 18 h and allowed 
to recover for 30 h. Gene expression of MBP was evaluated at 48 h by qRealTime PCR. Results are mean ± SEM. 
***p<0.001 vs. Control; ###p<0.001 vs. LPC 
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2. Neutralization of S100B prevents a microglia pro-inflammatory 
phenotype 
Along with demyelination, MS lesions are also characterized by microgliosis (Dyer et al., 
2005). Knowing that the inhibition of S100B does not prevent the increase of microglia density 
although it prevents the release of cytokines on our ex vivo demyelinating model (Barateiro et 
al., 2015), we decided to characterize the populations of reactive microglia in our COSC at 48 h 
post-LPC, by flow cytometry. Generally it is accepted that pro-inflammatory activated microglia 
is characterized as CD11bhigh, CD86high, CD45dim hi and F4/80high staining (Devarajan et al., 2014). 
 
 
Figure III. 2. S100B abrogation significantly decreases CD11b+/CD86+ microglia population induced by LPC-
demyelination. Cerebellar organotypic slice cultures were treated with LPC, at 7 days in vitro, in presence or absence 
of S100B and IgG antibodies, during 18 h and allowed to recover for 30 h. Dissociated slices were stained with CD11b- 
and CD86-specific monoclonal antibodies and analyzed by flow cytometry. (A) Data are expressed as mean of 
percentage of CD11b+ and (B) CD11b+/CD86+ cells ± SEM. ***p<0.001 and *p<0.05 vs. Control; ###p<0.001 and #p<0.05 
vs. LPC. (C) Representative images of cytograms are showed. 
 
As shown in Figure III. 2 A, treatment with LPC induced an increase of the population of 
more reactive microglia expressing CD11b (from 36.99% to 52.26%, p<0.05), which is prevented 
by anti-S100B neutralization. Next, we analyzed which CD11b+ population also expressed the 
pro-inflammatory cell surface receptors CD86, CD45 and F4/80. Figure III. 2 B clearly shows that 
LPC treatment increases the number of CD11b+/CD86+ microglia (from 3.88% to 49.75%, 
p<0.001), which is partially prevented by S100B neutralization by ~50% (p<0.001), while IgG had 
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no effect. These results show that, blockade of S100B may prevent a pro-inflammatory 
phenotype, as demonstrated by a significant reduction on CD11b+/CD86+ microglia population. 
On the other hand, we saw no differences between control and LPC, or even anti-S100B 
treatments in the other markers (Table III. 1), suggesting that demyelination did not influence 
their expression. 
 
Table III. 1. Demyelination or antibodies treatment on cerebellar organotypic slice cultures do not change the 
percentage of CD11b-positive cells that express F4/80 and CD45 markers. 
 CD11b+ F4/80+ CD11b+ CD452+ 
Control 63.06 % ± 8.04 % 16.03 % ± 7.01 % 
LPC 65.56 % ± 7.24 % 20.58 % ± 7.25 % 
LPC + anti-S100B 60.08 % ± 7.07 % 24.78 % ± 5.97 % 
LPC + IgG 61.86 % ± 6.94 % 22.25 % ± 7.05 % 
Cerebellar organotypic slice cultures were treated with LPC, at 7 days in vitro, in presence or absence of S100B or IgG 
antibodies, during 18 h and allowed to recover for 30 h. Dissociated slices were stained with CD11b-, F4/80- and 
CD45-specific monoclonal antibodies and analyzed by flow cytometry. Data are expressed as mean of percentage of 
positive cells ± SEM. 
 
3. Abrogation of S100B shifts microglia from a pro-inflammatory 
phenotype to a more neuroprotective one 
As mentioned above, MS lesions are characterized by microglia activation that lead to 
the secretion of pro-inflammatory cytokines and inflammasome-related proteins production 
that enhance the inflammatory response, contributing to disease progression (Benarroch, 2013; 
Vainchtein et al., 2014). Moreover, NLRP3 inflammasome, a complex involved in the maturation 
and secretion of pro-inflammatory molecules, have recently been associated with MS pathology. 
Once we have shown that S100B inhibition seems to prevent a pro-inflammatory response from 
microglia, we decided to explore the expression of these several inflammatory mediators upon 
demyelination and in the presence of anti-S100B antibody. 
As shown in Figure III. 3, LPC-induced demyelination increased the expression of 
cytokines TNF-α and IL-1β but decreased the IL-6 expression (1.46-, 6.24- and 0.35-fold, p<0.01 
and p<0.001, respectively). Anti-S100B treatment partially prevented LPC-induced alterations in 
cytokine expression (~56.52%, 63.17% and 76.92%, p<0.01, respectively), while no significant 
changes was observed upon IgG treatment. These results confirm the stimulation of an 
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inflammatory response upon demyelination and suggesting the involvement of S100B in 
cytokine release by microglial cells. 
 
Figure III. 3. S100B neutralization prevents the increase of TNF-α and IL-1β expression and the inhibition of IL-6 
expression induced by LPC-demyelination. Cerebellar organotypic slice cultures were exposed to LPC at 7 days in 
vitro, in presence or absence of S100B and IgG antibodies, during 18 h and allowed to recover for 30 h. Gene 
expression of TNF-α, IL-1β and IL-6 were evaluated at 48 h by qRealTime PCR. Results are mean ± SEM. ***p<0.001 
and **p<0.01 vs. Control; ###p<0.001 and ##p<0.01 vs. LPC. 
 
Inflammasomes are cytosolic sensors that detect alterations and are involved in 
maturation and release of pro-inflammatory cytokines, such as HMGB1, IL-1β and IL-18 (Inoue 
and Shinohara, 2013; Lu et al., 2013). The NLRP3 inflammasome consists of three proteins that 
has already been associated with MS development (Inoue and Shinohara, 2013). As we have 
previously observed, a marked increase of IL-1β expression upon demyelination and its 
protection after S100B inhibition, we next evaluated the gene expression of the other 
inflammasome-associated molecules. 
 
Figure III. 4. S100B neutralization prevents NLRP3 activation and inflammasome-related molecules expression 
induced by LPC-demyelination. Cerebellar organotypic slice cultures were exposed to LPC at 7 days in vitro, in 
presence or absence of S100B and IgG antibodies, during 18 h and allowed to recover for 30 h. (A) Gene expression 
of HMGB1, IL-18 and NLRP3 were evaluated at 48 h by qRealTime PCR. (B) Protein expression of HMGB1 was 
evaluated at 48 h by Western Blot. Results are mean ± SEM. ***p<0.001 and **p<0.01 vs. Control and ###p<0.001, 
##p<0.01 and #p<0.05 vs. LPC. 
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LPC markedly increased the expression of NLRP3 (4.75-fold, p<0.001), as well as that of 
cytokines that are processed by the inflammasome, HMGB1 and IL-18 (4.05- and 3.28-fold, 
p<0.001, respectively), as depicted in Figure III. 4 A. Neutralization of S100B prevented the 
expression of all inflammasome-related proteins (77.05%, 110.53% and 73.07%, p<0.001, for 
HMGB1, IL-18 and NLRP3, respectively). We next confirm whether protein expression was also 
altered in the same way for HMGB1. As demonstrated in Figure III. 4 B, HMGB1 was increased 
upon demyelination (2.37-fold, p<0.05) and, co-incubation with anti-S100B antibody reduced 
HMGB1 protein expression by 152.55%, p<0.01, although IgG incubation also seemed to have 
partial effect in these protein levels. All these results corroborate that we may decrease the 
inflammatory environment related to microglia activation with S100B neutralization. 
Since we observed a decrease in the release of pro-inflammatory molecules in the 
presence of S100B at physiological levels, we then looked at markers usually identified in M1 
pro-inflammatory microglia phenotype. 
 
Figure III. 5. S100B neutralization prevents the increase of MHC-II, iNOS and CEBP-α expression induced by LPC-
demyelination. Cerebellar organotypic slice cultures were exposed to LPC at 7 days in vitro, in presence or absence 
of S100B and IgG antibodies, during 18 h and allowed to recover for 30 h. Gene expression of MHC-II, iNOS and CEBP-
α were evaluated at 48 h by qRealTime PCR. Results are mean ± SEM. ***p<0.001 vs. Control; ##p<0.01 and #p<0.05 
vs. LPC. 
 
LPC-induced demyelination promoted a marked increase of gene expression of M1 cell 
surface markers MHC class II, iNOS and CEBP-α (7.87-, 8.51- and 4.85-fold, p<0.01, respectively), 
as presented in Figure III. 5. Interestingly, S100B blockade was able to prevent these expression 
for more than 60% (p<0.05), indicating a reduced M1 microglia polarization when elevated levels 
of S100B are neutralized in the culture medium. Antiserum treatment partially reduced MHC-II 
and iNOS expression suggesting a possible action at this markers. 
Microglia are rapidly activated in the CNS in response to several injuries, including 
inflammation. TLRs, an important member of pattern recognition receptors family, are 
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considered to be involved in MS pathology. Since there are studies showing the elevated 
expression of both TLR2 and TLR4 in MS patients (Miranda-Hernandez and Baxter, 2013), we 
decided to analyze the gene expression of these receptors. 
 
Figure III. 6. S100B inhibition prevents the alterations of TLR2/4 expression induced by LPC-demyelination. 
Cerebellar organotypic slice cultures were exposed to LPC at 7 days in vitro, in presence or absence of S100B and IgG 
antibodies, during 18 h and allowed to recover for 30 h. (A) Gene expression of TLR2 and TLR4 were evaluated at 48 
h by qRealTime PCR. (B) Protein expression of TLR4 was evaluated at 48 h by Western Blot. Results are mean ± SEM. 
***p<0.001 and **p<0.01 vs. Control; ###p<0.001 and ##p<0.01 vs. LPC. 
 
Accordingly with previous studies, both mRNA and protein TLR4 levels were increased 
upon demyelination (1.59- and 2.69-fold, p<0.01, respectively) possibly indicating an attempt of 
microglia to respond to an inflammatory stimulus (Figure III. 6 A, B). S100B inhibition prevented 
both LPC-induced TLR4 gene and protein expression (179.66% and 72.78%, p<0.001, 
respectively). However, also IgG co-incubation decreased TLR4 expression suggesting a potential 
effect of the antiserum. Concerning TLR2, its gene expression was decreased by LPC-induced 
demyelination (0.53-fold, p<0.001), what was abrogated by anti-S100B co-incubation to control 
levels (p<0.01). These results indicating that the inflammatory response may not occur through 
TLR2 pathway (Figure III. 6 A). 
Having confirmed the reduction of a pro-inflammatory phenotype with S100B inhibition, 
and knowing that microglia are the most responsible for inflammatory cytokine production, we 
evaluated whether microglia could be shifting from a M1 to a M2 phenotype with S100B 
blockade. In this regard, we analyzed COSC lysates 48 h after LPC treatment for different M2-
like gene expression. 
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Figure III. 7. S100B neutralization slightly intensifies the increase of Arg1 and FIZZ-1 expression induced by LPC-
demyelination. Cerebellar organotypic slice cultures were exposed to LPC at 7 days in vitro, in presence or absence 
of S100B and IgG antibodies, during 18 h and allowed to recover for 30 h. Gene expression of Arg1 and FIZZ-1 were 
evaluated at 48 h by qRealTime PCR. Results are mean ± SEM. ***p<0.001 and **p<0.01 vs. Control. 
 
So first we looked at Arg1 and FIZZ-1 expression (Figure III. 7), LPC-induced 
demyelination markedly increased these markers (6-75- and 2.45-fold for Arg1 and FIZZ-1, 
p<0.01, respectively), corroborating previous studies that show an increased M2 phenotype 
when remyelination is beginning (Miron et al., 2013). 
Neutralization of S100B did not significantly change the expression of both Arg1 and 
FIZZ-1 compared to LPC treated COSC (7.08- and 2.99-fold for Arg1 and FIZZ-1, respectively), 
suggesting that blockade of excessive amounts of S100B did not increase a microglia shift to a 
M2 phenotype increase. On the other hand, when other M2 microglial markers were analyzed, 
such as TGF-β and SOCS-1 (Figure III. 8), LPC-induced demyelination still markedly increased 
these markers (2.40- and 15.13-fold for TGF-β and SOCS-1, p<0.01, respectively), while S100B 
neutralization clearly decreased their expression to near control levels (0.86- and 1.83-fold for 
TGF-β and SOCS-1, p<0.01, respectively). Collectively, these results suggest that neutralization 
of S100B although preventing an exacerbated M1 phenotype microglia does not promote the 
shift of that microglia to a M2 phenotype. Curiously, also in here IgG co-incubation had an effect, 
reducing LPC-induced M2-markers expression but with a different trend than anti-S100B, 
indicating that although the antiserum may have an effect it does not completely mask the real 
anti-S100B action. 
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Figure III. 8. Inhibition of S100B neutralization diminished TGF-β and SOCS-1 expression induced by LPC-
demyelination. Cerebellar organotypic slice cultures were exposed to LPC at 7 days in vitro, in presence or absence 
of S100B and IgG antibodies, during 18 h and allowed to recover for 30 h. Gene expression of TGF-β and SOCS3 were 
evaluated at 48 h by qRealTime PCR. Results are mean ± SEM. ***p<0.001 and **p<0.01 vs. Control; ###p<0.001, 
##p<0.01 and #p<0.05 vs. LPC. 
 
Collectively, these results suggest that neutralization of S100B although preventing an 
exacerbated M1 phenotype microglia does not promote the shift of that microglia to a typical 
M2 phenotype, but may reduce their activation state due to a less demyelinated and  
inflammatory milieu. 
 
4. Neutralization of S100B change microglia phagocytic ability 
An important neuroprotective role of microglial cells is their ability to phagocyte, playing 
a crucial role in CNS both in pathology and tissue regeneration (Goldmann and Prinz, 2013; 
Kettenmann et al., 2011). Therefore, we explored the effect of S100B in microglia phagocytic 
properties by microglia immunohistochemistry with Iba-1 antibody following exposure to 
fluorescent zymosan-coated beads. 
As illustrated in Figure III. 9, treatment with LPC decreased both the number of 
phagocytosed beads per cell (0.49-fold, p<0.001) and the number of phagocyting microglia 
(0.41-fold, p<0.01). Interestingly, results show that there are an increase in the number of 
microglial cells that phagocyte after co-incubation of LPC with anti-S100B (1.00-fold, p<0.01), 
while the number of cells phagocyting a higher number of beads is also increased by S100B 
neutralization when different cutoffs of beads are analyzed (Figure III. 9 B), namely for less than 
20 beads. However, once again we see a partial effect also for IgG co-incubation. 
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Figure III. 9. Blocking S100B increases the number of phagocytic cells following demyelination. Cerebellar 
organotypic slice cultures were exposed to LPC at 7 days in vitro, in presence or absence of S100B and IgG antibodies, 
during 18 h and allowed to recover for 30 h. Slices are incubated with fluorescent latex beads to measure the 
phagocytic ability of microglial cells, by immunohistochemistry. (A) Confocal images showing the ingestion of the 
fluorescent beads (green) by Iba-1 (red) positive microglia in COSC. (B) Number of microglia phagocytosing 0, ≤10, 11-
20, 21-30, and >30 beads, (C) number of phagocytosed beads per cell and the (D) number of microglial cells that 
phagocyte were counted. Results are mean ± SEM. ***p<0.001 and **p<0.01 vs. Control; ##p<0.01 vs. LPC. 
 
5. S100B inhibition tries to recover the neuron-microglia communication 
Fractalkine (CX3CL1) has a role in specific communication with microglia, the only cells 
in the CNS that express the correspondent receptor, CX3CR1 (Harrison et al., 1998). Fractalkine 
is highly expressed in neurons, in the normal brain, allowing the hyporesponsiveness of microglia 
due to its ability to inhibit microglial activation. Loss of fractalkine or its receptor expression 
could impair this neuron-microglia dialogue leading to microglial activation (Zujovic et al., 2000). 
Thus, and considering that the fractalkine/CX3CR1 signaling plays a role in neuroinflammatory 
and autoimmune diseases of the CNS, we next explored the expression of fractalkine and 
CX3CR1 upon demyelination and in the presence of anti-S100B antibody to understand the role 
of S100B in this dialogue. 
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Figure III. 10. S100B neutralization tries to recover the neuron-microglia communication lost by LPC-demyelination. 
Cerebellar organotypic slice cultures were exposed to LPC at 7 days in vitro, in presence or absence of S100B and IgG 
antibodies, during 18 h and allowed to recover for 30 h. Gene expression of CX3CR1 and CX3CL1 were evaluated at 
48 h by qRealTime PCR. Results are mean ± SEM. ***p<0.001 vs. Control. #p<0.05 vs. LPC. 
 
As depicted in Figure III. 10, treatment with LPC decreased the expression of fractalkine 
receptor CX3CR1 when compared with control (0.39-fold, p<0.001) rendering cells less 
responsive to CX3CL1, while increased the expression of the chemokine itself. Interestingly, 
CX3CR1 reduction is attenuated after S100B abrogation (~66%, p<0.05), whereas the expression 
of CX3CL1 is slightly increased after anti-S100B antibody co-incubation, suggesting an attempt 
to restore this mechanism of microglia deactivation. 
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IV. Discussion 
S100B is associated with different neurodegenerative pathologies, including MS. Indeed, 
increased levels of S100B have been detected in both CSF and post-mortem demyelinated 
plaques of MS patients. The development of these demyelinated lesions, one hallmark of MS, 
are a result of several mechanisms including gliosis, inflammation, demyelination, axonal loss 
and neuronal degeneration (Milo and Miller, 2014). Thus, with this thesis we proposed to study 
the role of S100B in MS associated microglia reactivity, using an ex vivo model of demyelination 
(Birgbauer et al., 2004). Firstly, we evaluated whether the expression of a protein constituent of 
myelin sheaths could be recovered, in the course of the demyelinating insult with LPC by 
neutralization of excessive S100B. Our results revealed that the expression of MBP mRNA was 
decreased after demyelinating insult, according with Birgbauer and collaborators, which 
reported a significant decrease in myelin marker expression (Birgbauer et al., 2004). 
Interestingly, treatment with anti-S100B antibody prevented this demyelination, as previously 
reported by us (Barateiro et al., 2015), increasing the MBP mRNA expression. These data suggest 
that the neutralization of S100B prevented an exacerbated demyelination by keeping S100B 
concentration close to physiological levels and, therefore, having a protective role on 
demyelinating event. 
In healthy CNS, microglial cells, which are constantly patrolling the parenchyma, are 
characterized by a ramified morphology and low levels of CD11b and F4/80, 
macrophage/microglia activation marker, and CD45 and CD86, M1 markers (Devarajan et al., 
2014; Ponomarev et al., 2013). As we known, microglia become active during CNS inflammation, 
acquiring phenotypic and morphologic changes in response to inflammation. These activated 
microglia are generally characterized as CD11bhigh/CD86high/F4/80high and CD45dim high (Devarajan 
et al., 2014; Ponomarev et al., 2005, 2013). It is difficult to differentiate CNS resident microglia 
from peripheral macrophages because they present a similar pattern, however, our 
demyelinating ex vivo model does not involve these peripheral type of cells. Accordingly with 
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previous studies, we observed an increase of activated microglia population upon 
demyelination, observed through CD11b augment, which suggests their increased ability to 
respond to an injury. Once having confirmed the activation of microglia after a demyelinated 
insult, we evaluated their phenotype analyzing the expression of M1 markers and we only 
observed an upregulation of CD86 in response to LPC stimulation. Notably, the effect of S100B 
neutralization diminished CD86 cell surface expression suggesting a reduction of this pro-
inflammatory phenotype. Ponomarev and collaborators, reported a decrease in the expression 
of reactive marker CD11b when microglia acquire the M2 phenotype (Ponomarev et al., 2013), 
our results showed that neutralization of S100B promoted a reduction in CD11b levels 
expression suggesting a shift of microglia phenotype into a more anti-inflammatory one. In turn, 
we also analyzed other M1 markers, such as F4/80 and CD45, which did not statistically differ 
between conditions, indicating that in our demyelinating ex vivo model those are not the best 
markers to detect changes in microglia phenotype. Moreover, the population of microglia 
expressing CD45 was very low, corroborating the concept that the expression of this marker may 
distinguish between CD45dim hi microglia from CD45high macrophages. 
Although they are often referred to have a “resting” phenotype under healthy 
conditions, microglia cells are constantly patrolling their milieu and, therefore, their activation 
due to any damage, may contribute to an inflammatory environment by the secretion of 
inflammatory factors. According to Donato and collaborators which reported an increase of pro-
inflammatory cytokines release with high S100B levels (Donato et al., 2013), our results showed 
an increase in the expression of first-line cytokines TNF-α and IL-1β upon a demyelinated insult, 
in parallel to an increased S100B expression as previously reported by us (Barateiro et al., 2015). 
Moreover, our data also showed that S100B blockade prevents this cytokine increase. Once 
these cytokines are mainly released by activated microglia, these results suggest a microglial 
shift from a pro-inflammatory phenotype to less inflammatory one. In addition, our results 
showed a demyelination-induced decrease in pro-inflammatory IL-6 mRNA expression that 
returned to control levels following S100B neutralization. In spite of the large number of studies 
that reported the role of IL-6 in MS pathology, there is still a great controversy. As already 
mentioned, several studies reported an increase in IL-6 mRNA expression in chronic lesions 
(Maimone et al., 1997; Woodroofe and Cuzner, 1993), CSF (Navikas et al., 1996) and in 
peripheral blood monocytes (Frei et al., 1991) from MS patients, showing that this cytokine is 
involved in MS progression. However, there are studies that particularly shown low IL-6 levels 
in chronic inactive lesions and in plaques with oligodendrocyte loss (Schönrock et al., 2000), 
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suggesting that the reduced IL-6 expression upon demyelination, observed in our results, may 
be associated with oligodendrocyte damage/death (Bø et al., 2013). 
During MS pathophysiology microglia are activated in response to demyelination and 
release different inflammatory cytokines. Recently, some studies suggest the involvement of 
NLRP3 inflammasome on MS and EAE progression (Inoue and Shinohara, 2013). As mentioned 
above, inflammasomes are involved in maturation and release of cytokines. Indeed, IL-1β, 
HMGB1 and IL-18 are cytokines matured by NLRP3 inflammasome. HMGB1, a cytokine involved 
in the start of CNS inflammatory response, is increased in MS and EAE lesions (Andersson et al., 
2008). IL-18, a pro-inflammatory cytokine has also been revealed to be increased in MS patients 
(Sedimbi et al., 2013). Corroborating these studies, our results showed an increased expression 
of NLRP3, HMGB1 and IL-18 upon LPC-induced demyelination. Interestingly, there are a manifest 
reduction of inflammasome-related molecules by neutralization of S100B, indicating that 
excessive S100B expression following demyelination is not only exacerbating cytokine 
expression but also their maturation into active forms. 
In the activated state, microglia exhibit an upregulation of several markers according to 
the acquired phenotype. Particularly, in response to demyelination, pro-inflammatory microglia 
may increase the expression of several inflammatory markers, including MHC-II, iNOS and CEBP-
α. It has been demonstrated that classically activated microglia increased the expression of 
CEBP-α after brain injury, indicating that this transcription factor may regulate microglial 
function during brain damage (Walton et al., 1998). Also, Ponomarev and collaborators showed, 
in EAE model, an augmented expression of CEBP-α associated with the upregulation of other M1 
markers, such as MHC-II and iNOS (Ponomarev et al., 2011). Our ex vivo model also showed an 
increase of these pro-inflammatory markers in response to LPC thus corroborating these 
findings. Interestingly, the inhibition of excessive S100B in the milieu appears to be effective in 
the prevention of the expression of these cytokines, corroborating once again that S100B 
blockade reduces M1 pro-inflammatory microglia phenotype.  
MS is a chronic disorder where activated microglia play an important immune response. 
Microglia sensor danger/stranger signals activating the TLRs (Glass et al., 2010). Once TLRs are 
engaged, it initiates a cascade of events culminating into the activation of the transcription 
factor NF-κB and contribute to inflammation (Kettenmann et al., 2011). In this context, TLRs 
have been shown to be implicated in several CNS diseases including MS (Miranda-Hernandez 
and Baxter, 2013). Our results showed an augment of TLR4 but not of TLR2 gene expression 
upon demyelinated conditions, indicating that in our model TLR4 is possibly more responsible 
for microglia activation than TLR2. Moreover, the treatment with anti-S100B prevented the 
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increase of TLR4 and maintained the TLR2 expression at control levels, indicating that excessive 
S100B may also be exacerbating inflammation through TLR4. 
In turn, anti-inflammatory microglia, usually found in initial remyelination, are 
characterized by upregulated Arg1, FIZZ-1, TGF-β and SOCS-1, amongst many other markers 
(Chhor et al., 2013; Correale, 2014; David and Kroner, 2011; Hu et al., 2014; Ponomarev et al., 
2013; Wilson, 2014). In accordance with these previous studies, 48 h after a demyelinating insult 
there are a marked upregulation of Arg1 and FIZZ-1 gene expression. Curiously, S100B 
neutralization did not significantly changes these levels suggesting a maintenance of M2 
phenotype in the presence of low levels of S100B protein. However, TGF-β and SOCS-1 
expression was almost completed abrogated by the inhibition of S100B. Besides the important 
immunosuppressive role of TGF-β described in relapsing EAE and MS, where it prevents T cells 
from entering into CNS, there are evidences that this cytokine can increase Th17 production in 
inflammatory tissues further promoting pro-inflammatory gene expression in CNS tissue 
(Mirshafiey and Mohsenzadegan, 2009). So, the reduction of TGF-β levels observed by S100B 
neutralization may suggest an important involvement of S100B in Th17 response and 
recruitment to the CNS, which should be further elucidated in in vivo systems. In addition, 
despite of microglia phenotypes have been considered separable stages, different populations 
with distinct phenotypes are simultaneously present upon inflammatory conditions. As already 
mentioned, SOCS-1 inhibits the expression of pro-inflammatory markers at high levels (Davey et 
al., 2006). In addition, as we already demonstrated, there is an increase of several pro-
inflammatory markers expression upon demyelination. However, in accordance with Kakhki and 
collaborators that showed an increase of SOCS-1 expression in MS patients, our results revealed 
that SOCS-1 mRNA was overexpressed in a demyelinated condition (Kakhki et al., 2015). Thus, 
the fact that there is an increased expression of SOCS-1 after the incubation with LPC may 
indicate a response from microglia to fight the high inflammatory burden. 
Phagocytosis is a crucial mechanism for clearance of pathogens, dying cells and debris 
in order to maintain tissue health. Microglia are able to phagocyte either debris, including myelin 
debris, and apoptotic cells that are internalized through phosphatidylserine receptors, 
stimulating an anti-inflammatory response; or infectious pathogens through TLRs, inducing the 
release of pro-inflammatory cytokines (Napoli and Neumann, 2010). While M1 microglia exert 
cytotoxic effects on neurons, M2 microglia exhibit phagocytic capacity promoting neurite 
outgrowth (Prinz and Priller, 2014). Here, we investigated the ability of microglia to phagocyte 
zymosan-coated latex beads, which would mimic the phagocytosis of a pathogen. LPC treatment 
reduced both the number of phagocytosed beads per cell as well as the number of phagocyting 
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microglia. These results may suggest that either microglia ability to phagocyte is reduced by LPC-
induced demyelination or that in the presence of demyelination, microglia has to phagocyte 
myelin debris and are no longer able to further phagocyte the beads to which they are exposed 
at the end of the 48 h post-LPC. Curiously, although S100B inhibition did not change the number 
of beads that microglia can phagocyte, we verified an increase of microglial cells that 
phagocytosed less beads. This data may suggest that microglia may show an enhanced 
phagocytic ability upon neutralization of excessive S100B or that there is less myelin debris to 
phagocyte and therefore microglia are more prone to zymosan-coated beads. To that, it would 
be interesting to investigate the co-localization of myelin and microglia in our model of 
demyelination to analyze the amount of myelin debris that have been already phagocytosed by 
microglia during culture period to better clarify this issue. 
An extensively described axis of communication between neurons and microglia is 
fractalkine-CX3CL1/CX3CR1. This signaling pathway is very important in the maintenance of 
microglia under a vigilant phenotype. Our results showed diminished mRNA expression of 
CX3CR1 but increased gene expression of its ligand after demyelination, suggesting a reduced 
response of microglia to CX3CL1. Cardona and collaborators showed that CX3CR1 deficient 
microglia overexpressed IL-1β and displayed neurotoxic activity indicating that this axis might 
be compromised during a demyelinated insult and that microglia can acquire an activated 
phenotype (Cardona et al., 2006). Furthermore, CX3CR1 knockout mice showed increased 
toxicity in response to LPS treatment and augmented neurodegeneration (Cardona et al., 2006). 
Although it has already been reported an augmented expression of CX3CR1 in inflammatory 
lesions of MS patients (Wollberg et al., 2014), our results suggest that in our ex vivo 
demyelination model the lack of fractalkine receptor may be involved in the activation of 
microglia into a pro-inflammatory phenotype releasing several inflammatory mediators and 
promoting neurodegeneration. We also verified that with S100B neutralization, the CX3CR1 
expression levels returned to control values, possibly as an attempt to restore this pathway, 
justifying why S100B protein, at physiological levels, was reported to prevent the activation of 
microglial cells (Zhang et al., 2011b). Regarding to fractalkine-CX3CL1, our results revealed an 
overexpression of this gene expression levels after LPC treatment and a slight increase upon co-
incubation with anti-S100B antibody. Many neurodegenerative and inflammatory disorders that 
are associated with increased microglial activation, including MS, show disruption of the 
fractalkine/CX3CR1 crosstalk. Transgenic mice that develop EAE spontaneously and mice 
actively immunized with proteolytic peptide display an augmented fractalkine in brain microglia 
(Sheridan and Murphy, 2013). Therefore, a CNS injury, mimicked into our model by LPC 
IV. Discussion 
 
46 
 
treatment, may be a trigger to increase CX3CL1 expression which may either contribute to 
disease progression or be a mechanism by which other cells attempt to stop microglia high 
reactivity shifting them to a quiescent/vigilant phenotype. 
IgG co-incubation appears to have a similar effect of S100B neutralization in some cases, 
which might indicate that an introduction of an IgG to the incubation medium may have an effect 
by itself which may mask the intended neutralization of S100B. Therefore, it would be 
interesting to investigate the role of additional S100B modulators that have been already 
demonstrated to play a role in preventing S100B-related damage in cancer and experimental 
traumatic brain injury, in our ex vivo model of demyelination (Capoccia et al., 2015; Kabadi et 
al., 2015; Zimmer et al., 2013). 
 
Concluding Remarks 
With this thesis we demonstrated, using an ex vivo COSC model, that LPC effectively 
induced demyelination through reduction of myelin protein expression and confirmed that the 
anti-S100B treatment partially prevent this demyelination. Moreover, we showed that the 
demyelinated insult induced an inflammatory environment resulting from the release of 
inflammatory molecules by activated microglia. On the other hand, the blockade of S100B seems 
to prevent the expression of pro-inflammatory mediators and promote the shift microglia to a 
damage repair phenotype with the increase of phagocytic ability (Figure IV. 1), although M2-like 
markers were not induced. Overall, our results strongly suggest that inhibition of excessive 
S100B upon demyelination prevents both demyelination and the exacerbation of the 
inflammatory milieu, possibly also affecting microglia activation and the recruitment of other 
immune cell to CNS parenchyma. Further studies on in vivo MS models will better clarify whether 
targeting of S100B can be a good therapeutic strategy to reduce damage and increase recovery 
in MS. 
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Figure IV. 1. Schematic representation of main findings. (A) In demyelinated conditions there is an upregulation of 
pro-inflammatory cytokines. (B) Blocking S100B showed a reduction of pro-inflammatory environment and an 
increased phagocytosis. 
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